The economics of a registry are decided by what happens after month twelve: whether participants keep reporting, whether follow-up data keeps arriving, and whether anyone can still afford to collect it.
Participants consent from home or in clinic, with re-consent flows ready for the amendments a decade-long registry will inevitably see. Teams using Castor eConsent have seen enrollment improve 2x to 5x.
Participants report from their own devices with automated reminders, and direct-to-patient technical support can be scoped for studies that need it, so a confused participant becomes a retained one instead of a lost one.
Castor Catalyst extracts the source data, shared by patients through a HIPAA release or FHIR or uploaded by sites, straight into the registry, cutting chart review from 39 minutes to 6 minutes per chart, with a person reviewing every value.
From first consent to final export, the registry lives on maintained, compliant infrastructure with a complete audit trail, not on a departmental database that retires with its builder.
Remote and on-site consent, guardian flows, and re-consent for amendments.
Castor eConsent
Electronic clinical outcome assessment (eCOA) surveys on participants’ own devices through the Castor Connect app, with direct-to-patient support available as a scoped service.
Castor eCOA and ePRO
Electronic data capture (EDC) with real-time edit checks, plus in-house data management when you want it: study build, query management, coding, and ongoing data review, so a small team can keep a large registry clean.
Castor EDC
Patients share their own records via HIPAA release or FHIR, and Catalyst extracts the source data, human-reviewed before anything enters the registry.
Castor Catalyst
A single national genetics and rare disease biobank runs 37,000+ subjects on Castor, growing year over year.
Castor’s longest-running registry has been capturing data for 127 months and counting. Common in rare disease, where progression data supports regulatory decisions.
A national colorectal cancer registry runs 17,600+ participants and 550,000+ datapoints on Castor, in a program designed to scale to 800,000+ patients.
Post-market clinical follow-up (PMCF) under the EU Medical Device Regulation runs on the same platform. See the dedicated medical device and PMCF solution and our guide to real-world evidence and PMCF registries.
A multi-center Type 2 Diabetes cohort tracks 4,300+ subjects, and a national bariatric surgery outcomes registry follows 1,400+ participants longitudinally.
Long-term follow-up (LTFU) obligations, including the 15-year horizons gene therapy programs face, stay affordable when follow-up comes straight from patients and their records, not only from site visits.
A four-person clinical team ran randomized controlled trials on Castor as part of a wider real-world evidence program that has produced 30+ peer-reviewed studies.
“Ease of use, adaptability, and reliability are three things that are really crucial in all these platforms.”
Fernando Correia, Senior Vice President of Clinical Affairs at Sword Health
A single national genetics and rare disease biobank has grown to 37,000+ subjects on Castor, while the platform’s longest-running registry has captured data continuously for 127 months and counting. Longevity is the proof registries actually need.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Castor patient registry software runs disease registries, natural history studies, and long-term follow-up on one connected platform, combining eConsent enrollment, ePRO follow-up, EDC data capture and management, and AI-assisted data extraction with human review. Castor has run 1,000+ registries to date, with 90 million+ datapoints captured across them.
Registry software has a different job than trial software. It has to tolerate protocol amendments and re-consents across years, let participants report without visiting a site, and keep follow-up affordable when the study outlives its original budget. That is why registries on Castor lean on direct-to-patient reporting, scoped patient-support options, and extraction workflows where patients share their records and Catalyst extracts the follow-up data, instead of sites re-typing it. For registry design and execution support, Castor’s real-world evidence services deliver studies up to 70% faster than traditional methods.
21 CFR Part 11 and GCPISO standardsGDPR and HIPAASecurity statement
Patient registry software is the system a registry runs on: it enrolls and consents participants, collects data from sites and from patients directly over months or years, keeps the dataset clean and auditable, and exports it for analysis or regulatory use. Castor combines eConsent, ePRO, EDC, and AI-assisted data extraction with human review on one platform, and has run 1,000+ registries to date.
A registry collects standardized data on a defined population over time, often for safety, outcomes, or post-market evidence. A natural history study is a registry-style design focused on how a disease progresses without intervention, common in rare disease and used to support regulatory decisions. Both run on the same Castor infrastructure, and the platform’s longest-running registry has been capturing data for 127 months and counting.
The platform’s longest-running registry has been capturing data for 127 months and counting, and a national biobank on Castor has grown to 37,000+ subjects year over year. Day to day, participants report from their own devices through ePRO and the Castor Connect app, with direct-to-patient technical support available as an optional, scoped service for studies that need it. At recruitment, a blinded decentralized screening study saw more than 98% screener completion and 90.5% survey completion.
Yes. Castor supports direct-to-patient registries: participants consent remotely with eConsent, report outcomes from their own devices, and patients can share their medical records through a HIPAA release or FHIR, and Castor Catalyst extracts the source data, with every extracted value reviewed by a person before it enters the record.
Yes. Post-market clinical follow-up (PMCF) registries under the EU Medical Device Regulation run on the same platform, with electronic case report forms, clinician-reported surveys, and exports structured for technical documentation. Castor has a dedicated medical device and PMCF solution.
Patients share their records via HIPAA release or FHIR, or sites upload source documents, and Castor Catalyst extracts the source data, proposing structured values for the registry’s data fields, and routes everything through human review before it enters the database. It reduces manual chart review from 39 minutes to 6 minutes per chart, which is what makes long follow-up affordable at registry scale.